<?xml version='1.0' encoding='utf-8'?>
<document id="23519656"><sentence text="Pharmacokinetics of coadministration of guanfacine extended release and methylphenidate extended release."><entity charOffset="40-50" id="DDI-PubMed.23519656.s1.e0" text="guanfacine" /><entity charOffset="72-87" id="DDI-PubMed.23519656.s1.e1" text="methylphenidate" /><pair ddi="false" e1="DDI-PubMed.23519656.s1.e0" e2="DDI-PubMed.23519656.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23519656.s1.e0" e2="DDI-PubMed.23519656.s1.e1" /></sentence><sentence text="α2-Adrenoceptor agonists are used adjunctively to psychostimulants in treating attention-deficit/hyperactivity disorder (ADHD) when psychostimulants alone do not sufficiently reduce symptoms" /><sentence text=" However, data on the pharmacokinetic profiles and safety of combination treatments in ADHD are needed" /><sentence text="" /><sentence text="The primary objective of this study was to evaluate the pharmacokinetic profiles of guanfacine extended release (GXR) and methylphenidate hydrochloride (MPH) extended release, alone and in combination"><entity charOffset="84-94" id="DDI-PubMed.23519656.s5.e0" text="guanfacine" /><entity charOffset="122-151" id="DDI-PubMed.23519656.s5.e1" text="methylphenidate hydrochloride" /><entity charOffset="153-156" id="DDI-PubMed.23519656.s5.e2" text="MPH" /><pair ddi="false" e1="DDI-PubMed.23519656.s5.e0" e2="DDI-PubMed.23519656.s5.e0" /><pair ddi="false" e1="DDI-PubMed.23519656.s5.e0" e2="DDI-PubMed.23519656.s5.e1" /><pair ddi="false" e1="DDI-PubMed.23519656.s5.e0" e2="DDI-PubMed.23519656.s5.e2" /><pair ddi="false" e1="DDI-PubMed.23519656.s5.e1" e2="DDI-PubMed.23519656.s5.e1" /><pair ddi="false" e1="DDI-PubMed.23519656.s5.e1" e2="DDI-PubMed.23519656.s5.e2" /></sentence><sentence text="" /><sentence text="This was an open-label, randomized, three-period crossover, drug-drug interaction study" /><sentence text="" /><sentence text="The study was conducted at a single clinical research center" /><sentence text="" /><sentence text="Thirty-eight healthy adults were randomized in this study" /><sentence text="" /><sentence text="Subjects were administered single oral doses of GXR (Intuniv(®); Shire Development LLC, Wayne, PA, USA) 4 mg, MPH (Concerta(®); McNeil Pediatrics, Titusville, NJ, USA) 36 mg, or GXR and MPH combined"><entity charOffset="110-112" id="DDI-PubMed.23519656.s13.e0" text="MPH" /><entity charOffset="186-188" id="DDI-PubMed.23519656.s13.e1" text="MPH" /><pair ddi="false" e1="DDI-PubMed.23519656.s13.e0" e2="DDI-PubMed.23519656.s13.e0" /><pair ddi="false" e1="DDI-PubMed.23519656.s13.e0" e2="DDI-PubMed.23519656.s13.e1" /></sentence><sentence text="" /><sentence text="Guanfacine, dexmethylphenidate (d-MPH), and l-methylphenidate (l-MPH) levels were measured with blood samples collected predose and up to 72 h postdose"><entity charOffset="0-10" id="DDI-PubMed.23519656.s15.e0" text="Guanfacine" /><entity charOffset="12-30" id="DDI-PubMed.23519656.s15.e1" text="dexmethylphenidate" /><entity charOffset="32-37" id="DDI-PubMed.23519656.s15.e2" text="d-MPH" /><entity charOffset="44-61" id="DDI-PubMed.23519656.s15.e3" text="l-methylphenidate" /><entity charOffset="63-68" id="DDI-PubMed.23519656.s15.e4" text="l-MPH" /><entity charOffset="143-151" id="DDI-PubMed.23519656.s15.e5" text="postdose" /><entity charOffset="34-41" id="DDI-PubMed.23519656.s15.e6" text="MPH" /><entity charOffset="65-72" id="DDI-PubMed.23519656.s15.e7" text="MPH" /><pair ddi="false" e1="DDI-PubMed.23519656.s15.e0" e2="DDI-PubMed.23519656.s15.e0" /><pair ddi="false" e1="DDI-PubMed.23519656.s15.e0" e2="DDI-PubMed.23519656.s15.e1" /><pair ddi="false" e1="DDI-PubMed.23519656.s15.e0" e2="DDI-PubMed.23519656.s15.e2" /><pair ddi="false" e1="DDI-PubMed.23519656.s15.e0" e2="DDI-PubMed.23519656.s15.e6" /><pair ddi="false" e1="DDI-PubMed.23519656.s15.e0" e2="DDI-PubMed.23519656.s15.e3" /><pair ddi="false" e1="DDI-PubMed.23519656.s15.e0" e2="DDI-PubMed.23519656.s15.e4" /><pair ddi="false" e1="DDI-PubMed.23519656.s15.e0" e2="DDI-PubMed.23519656.s15.e7" /><pair ddi="false" e1="DDI-PubMed.23519656.s15.e0" e2="DDI-PubMed.23519656.s15.e5" /><pair ddi="false" e1="DDI-PubMed.23519656.s15.e1" e2="DDI-PubMed.23519656.s15.e1" /><pair ddi="false" e1="DDI-PubMed.23519656.s15.e1" e2="DDI-PubMed.23519656.s15.e2" /><pair ddi="false" e1="DDI-PubMed.23519656.s15.e1" e2="DDI-PubMed.23519656.s15.e6" /><pair ddi="false" e1="DDI-PubMed.23519656.s15.e1" e2="DDI-PubMed.23519656.s15.e3" /><pair ddi="false" e1="DDI-PubMed.23519656.s15.e1" e2="DDI-PubMed.23519656.s15.e4" /><pair ddi="false" e1="DDI-PubMed.23519656.s15.e1" e2="DDI-PubMed.23519656.s15.e7" /><pair ddi="false" e1="DDI-PubMed.23519656.s15.e1" e2="DDI-PubMed.23519656.s15.e5" /><pair ddi="false" e1="DDI-PubMed.23519656.s15.e2" e2="DDI-PubMed.23519656.s15.e2" /><pair ddi="false" e1="DDI-PubMed.23519656.s15.e2" e2="DDI-PubMed.23519656.s15.e6" /><pair ddi="false" e1="DDI-PubMed.23519656.s15.e2" e2="DDI-PubMed.23519656.s15.e3" /><pair ddi="false" e1="DDI-PubMed.23519656.s15.e2" e2="DDI-PubMed.23519656.s15.e4" /><pair ddi="false" e1="DDI-PubMed.23519656.s15.e2" e2="DDI-PubMed.23519656.s15.e7" /><pair ddi="false" e1="DDI-PubMed.23519656.s15.e2" e2="DDI-PubMed.23519656.s15.e5" /><pair ddi="false" e1="DDI-PubMed.23519656.s15.e6" e2="DDI-PubMed.23519656.s15.e6" /><pair ddi="false" e1="DDI-PubMed.23519656.s15.e6" e2="DDI-PubMed.23519656.s15.e3" /><pair ddi="false" e1="DDI-PubMed.23519656.s15.e6" e2="DDI-PubMed.23519656.s15.e4" /><pair ddi="false" e1="DDI-PubMed.23519656.s15.e6" e2="DDI-PubMed.23519656.s15.e7" /><pair ddi="false" e1="DDI-PubMed.23519656.s15.e6" e2="DDI-PubMed.23519656.s15.e5" /><pair ddi="false" e1="DDI-PubMed.23519656.s15.e3" e2="DDI-PubMed.23519656.s15.e3" /><pair ddi="false" e1="DDI-PubMed.23519656.s15.e3" e2="DDI-PubMed.23519656.s15.e4" /><pair ddi="false" e1="DDI-PubMed.23519656.s15.e3" e2="DDI-PubMed.23519656.s15.e7" /><pair ddi="false" e1="DDI-PubMed.23519656.s15.e3" e2="DDI-PubMed.23519656.s15.e5" /><pair ddi="false" e1="DDI-PubMed.23519656.s15.e4" e2="DDI-PubMed.23519656.s15.e4" /><pair ddi="false" e1="DDI-PubMed.23519656.s15.e4" e2="DDI-PubMed.23519656.s15.e7" /><pair ddi="false" e1="DDI-PubMed.23519656.s15.e4" e2="DDI-PubMed.23519656.s15.e5" /><pair ddi="false" e1="DDI-PubMed.23519656.s15.e7" e2="DDI-PubMed.23519656.s15.e7" /><pair ddi="false" e1="DDI-PubMed.23519656.s15.e7" e2="DDI-PubMed.23519656.s15.e5" /></sentence><sentence text=" Safety evaluations included treatment-emergent adverse events (TEAEs), vital signs, and electrocardiograms (ECGs)" /><sentence text="" /><sentence text="Thirty-five subjects completed the study" /><sentence text=" Analyses of the 90 % confidence intervals (CIs) for the geometric mean ratios of the maximum plasma concentration (Cmax) and area under the concentration-time curve extrapolated to infinity (AUC∞) values for guanfacine and d-MPH following administration of GXR or MPH alone or combined met strict bioequivalence criteria (90 % CIs within the interval of 0"><entity charOffset="209-219" id="DDI-PubMed.23519656.s19.e0" text="guanfacine" /><entity charOffset="226-235" id="DDI-PubMed.23519656.s19.e1" text="MPH" /><entity charOffset="265-274" id="DDI-PubMed.23519656.s19.e2" text="MPH" /><entity charOffset="224-233" id="DDI-PubMed.23519656.s19.e3" text="d-MPH" /><pair ddi="false" e1="DDI-PubMed.23519656.s19.e0" e2="DDI-PubMed.23519656.s19.e0" /><pair ddi="false" e1="DDI-PubMed.23519656.s19.e0" e2="DDI-PubMed.23519656.s19.e3" /><pair ddi="false" e1="DDI-PubMed.23519656.s19.e0" e2="DDI-PubMed.23519656.s19.e1" /><pair ddi="false" e1="DDI-PubMed.23519656.s19.e0" e2="DDI-PubMed.23519656.s19.e2" /><pair ddi="false" e1="DDI-PubMed.23519656.s19.e3" e2="DDI-PubMed.23519656.s19.e3" /><pair ddi="false" e1="DDI-PubMed.23519656.s19.e3" e2="DDI-PubMed.23519656.s19.e1" /><pair ddi="false" e1="DDI-PubMed.23519656.s19.e3" e2="DDI-PubMed.23519656.s19.e2" /><pair ddi="false" e1="DDI-PubMed.23519656.s19.e1" e2="DDI-PubMed.23519656.s19.e1" /><pair ddi="false" e1="DDI-PubMed.23519656.s19.e1" e2="DDI-PubMed.23519656.s19.e2" /></sentence><sentence text="80-1" /><sentence text="25)" /><sentence text=" Overall, combining GXR and MPH did not alter the pharmacokinetic parameters of either medication"><entity charOffset="28-32" id="DDI-PubMed.23519656.s22.e0" text="MPH" /></sentence><sentence text=" Sixteen subjects (42" /><sentence text="1 %) had at least one TEAE" /><sentence text=" The most commonly reported TEAEs included headache and dizziness following GXR, MPH, and GXR and MPH combined"><entity charOffset="81-83" id="DDI-PubMed.23519656.s25.e0" text="MPH" /><entity charOffset="98-100" id="DDI-PubMed.23519656.s25.e1" text="MPH" /><pair ddi="false" e1="DDI-PubMed.23519656.s25.e0" e2="DDI-PubMed.23519656.s25.e0" /><pair ddi="false" e1="DDI-PubMed.23519656.s25.e0" e2="DDI-PubMed.23519656.s25.e1" /></sentence><sentence text=" Two subjects had clinically significant abnormalities in ECG results following coadministration: both events were mild and resolved the same day" /><sentence text="" /><sentence text="In this short-term, open-label study of healthy adults, coadministration of GXR and MPH did not result in significant pharmacokinetic drug-drug interactions"><entity charOffset="84-86" id="DDI-PubMed.23519656.s28.e0" text="MPH" /></sentence><sentence text=" No unique TEAEs were observed with coadministration of GXR and MPH compared with either treatment alone"><entity charOffset="64-66" id="DDI-PubMed.23519656.s29.e0" text="MPH" /></sentence><sentence text="" /></document>